Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Eisai R&D Management Co., Ltd. has 11 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a different examiner, with 11 distinct examiners across 9 distinct art units. The portfolio is therefore broadly examiner-dispersed with some technical grouping.
LEWIS, CAMRYN BROOKE is the busiest examiner, with 1 pending matter. Counsel should coordinate biological and pharmaceutical terminology across the nine art units, but should develop application-specific responses because the supplied data shows no repeated examiner assignment.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 2 (20%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863738 | SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 133d overdue |
| 18846082 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS | ELENISTE, PIERRE PAUL | — |
| 18845692 | METHOD FOR QUANTIFYING ACTIVE OREXIN A | DUNN, MCKENZIE A | — |
| 18690679 | BIOMARKERS FOR STING AGONISTS AND METHODS OF USING THE SAME | BELLAH, JEFFREY LAWRENCE | — |
| 18557876 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | YU, DELPHINUS DOU YI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 133d overdue |
| 18188716 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | SIMMONS, CHRIS E | 42d |
| 18863738 | SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE | JARRELL, NOBLE E | — |
| 18846082 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS | ELENISTE, PIERRE PAUL | — |
| 18845692 | METHOD FOR QUANTIFYING ACTIVE OREXIN A | DUNN, MCKENZIE A | — |
| 18722917 | CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF | JAVANMARD, SAHAR | — |
| 18577174 | BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT | LEE, YIE CHIA | — |
| 17757672 | USE OF LEMBOREXANT FOR TREATING INSOMNIA | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1699 | 1 |
| 1678 | 1 |
| 1683 | 1 |
| 1642 | 1 |
| 1636 | 1 |
| 1641 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863738 | SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18846082 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS | ELENISTE, PIERRE PAUL | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18845692 | METHOD FOR QUANTIFYING ACTIVE OREXIN A | DUNN, MCKENZIE A | 1678 | §101§102§103 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18722917 | CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF | JAVANMARD, SAHAR | 1622 | §103Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18690679 | BIOMARKERS FOR STING AGONISTS AND METHODS OF USING THE SAME | BELLAH, JEFFREY LAWRENCE | 1683 | §103§112Other | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18577174 | BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT | LEE, YIE CHIA | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18557876 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | YU, DELPHINUS DOU YI | 1636 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 1641 | §103§112 | Final Rejection | 133d overdue | Pending | Mar 23, 2023 |
| 18188716 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | SIMMONS, CHRIS E | 1622 | §103Other | Non-Final OA | 42d | Pending | Mar 23, 2023 |
| 17757672 | USE OF LEMBOREXANT FOR TREATING INSOMNIA | MOU, LIYUAN | 1628 | §103DP | Non-Final OA | — | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEisai R&D Management Co., Ltd. has 10 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
Noble E Jarrell has the most, with 1 of Eisai R&D Management Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
